Powered By
If you’re living with stage 4 triple-negative breast cancer (TNBC) — also called metastatic triple-negative breast cancer — you may have questions about what the diagnosis means for your future. Survival statistics can provide a general picture, but they can’t predict exactly what will happen for any one person.
This article will cover triple-negative breast cancer survival rates and different factors that can affect your prognosis (outlook). Talk with your doctor about any questions or concerns — they can help you better understand your individual situation.
Stage 4 is the most advanced stage of breast cancer. It’s important to understand the complex factors that affect survival rates in stage 4 TNBC.
TNBC is a faster growing type of breast cancer that’s challenging to treat. This is partly because the cancer cells don’t have the following proteins:
These receptors can be used as targets for treatment therapies. Since TNBC breast cancer cells don’t have HER2 or hormone receptors to target, TNBC has fewer treatment options. Compared to other subtypes of breast cancer, TNBC is more aggressive, often grows and spreads more quickly, and has a poorer prognosis.
To better understand cancer prognosis, researchers often look at survival rates in large groups of people. Depending on the questions they’re asking, different types of survival rates may be used.
Researchers often use the five-year relative survival rate to compare survival in people with cancer with survival in the general population. It shows how likely people with a certain cancer are to be alive five years after diagnosis compared with people who don’t have that cancer.
The Surveillance, Epidemiology, and End Results Program (SEER) database provides the National Cancer Institute with data to keep track of cancer survival rates.
According to the American Cancer Society, the five-year relative survival rate for TNBC that has spread to other parts of the body is 15 percent. SEER calls this “distant” cancer, which most closely matches stage 4, or metastatic, TNBC.
This means that people with stage 4 disease are about 15 percent as likely as the general population to still be alive in five years.
Another way to look at TNBC prognosis is overall survival. This measures the percentage of people with a certain type of cancer who are still alive after a period of time — usually five years. It’s important to note that overall survival simply looks at whether people with cancer are alive or have died rather than the specific cause of death.
Overall survival rates may be different across different study populations. In studies done in Western populations, the five-year overall survival rate for stage 4 TNBC has ranged from 4 percent to 20 percent. This means that up to 20 percent of people with stage 4 TNBC are expected to still be alive five years after diagnosis.
In clinical trials that are testing possible new treatments for cancer, progression-free survival may be used to figure out how well the treatment is working. Progression-free survival refers to how long people can live without the cancer getting worse during and after treatment.
Progression-free survival is a different outcome than overall survival. This measurement can help you to know whether a cancer treatment might help you live longer without your cancer progressing. A treatment may delay cancer growth or spread without necessarily proving that it helps people live longer overall.
While being diagnosed at a young age doesn’t necessarily mean a worse outcome, risk factors — as well as a person’s medical history — can affect TNBC prognosis.
TNBC doesn’t affect all groups equally.
Researchers are still studying why these differences occur. Lower income and reduced access to healthcare contribute to worse outcomes, and lifestyle and genetic factors may also play a role.
Although research is helping explain and address these gaps, more work is needed to improve access to treatment and survival for all groups.
TNBC can come back after treatment or may not respond well to therapy. When metastatic TNBC relapses or doesn’t respond to treatment, it is generally linked to a poorer prognosis.
In stage 4 TNBC, breast cancer cells spread and form tumors in other parts of the body. Where these distant tumors first spread can affect your prognosis.
One study compared overall survival rates across different sites (locations) of metastasis. Researchers found that when the cancer first spread to the brain, it led to the shortest survival time. On the other hand, when the cancer spread first to the lung or the bone, people had the longest survival rates.
These results show that your prognosis can depend a lot on where metastasis first occurs and, of course, your access to cutting-edge treatments.
Other health conditions and lifestyle factors may also affect survival. One study found that people with TNBC who had a higher body mass index (BMI) had worse outcomes than those with a lower BMI. One possible reason is that excess body fat can increase inflammation, which may support cancer growth.
Though the outlook for stage 4 TNBC may not look very positive, you shouldn’t lose hope. General statistics can’t predict how individual cases will play out. Reach out to your oncology care team to learn how you can improve your chance at a longer life.
Until recently, treatments for TNBC were primarily surgery, chemotherapy, and radiation. However, breast cancer research has made significant progress developing new effective treatments.
As researchers have learned more about TNBC, treatment options have expanded to include targeted therapies aimed at traits other than hormones or protein receptors (which aren’t a factor in TNBC).
One of the newest targeted treatment strategies for TNBC is using biomarker-driven care that matches specific tumor traits to targeted medicines.
For example, some people with metastatic TNBC who have an inherited BRCA1 or BRCA2 mutation (change) may be treated with olaparib (Lynparza) or talazoparib (Talzenna), which are PARP inhibitors. These medications block the PARP enzyme that normally repairs damaged cell DNA. Blocking this mechanism in cancer cells that have BRCA 1 or BRCA2 mutations causes the cells to die. PARP inhibitors can help keep the cancer from getting worse for longer.
Your doctor may recommend immunotherapy drugs that can specifically target certain proteins in cancer cells. These therapies may be used alone or in combination with chemotherapy to shrink tumors before surgery.
Antibody-drug conjugates combine targeted therapy with chemotherapy to target cancer cells without damaging healthy cells. The U.S. Food and Drug Administration (FDA) first approved sacituzumab govitecan-hziy (Trodelvy) in 2021 and expanded its treatment profile in combination with chemotherapy in 2026.
The drug contains a monoclonal antibody that targets and binds to a protein on cancer cells. It then delivers a drug into the cancer cell that causes its death.
Sacituzumab govitecan-hziy is approved for use as a secondary TNBC treatment for people who can’t take PARP inhibitors and for whom surgery isn’t an option or the cancer is spreading.
This medication is also approved as a first-line triple-negative breast cancer treatment in combination with pembrolizumab (Keytruda) with or without berahyaluronidase alfa-pmph (Keytruda Qlex) for some people with advanced or metastatic TNBC.
For metastatic TNBC, chemotherapy is a common treatment and may be used alone or with other cancer treatments. Surgery may sometimes be used to relieve symptoms or treat cancer in a specific area.
If your cancer stops responding to treatment or if you’ve already had chemotherapy, your oncologist (cancer specialist) may recommend a more specialized type of chemotherapy or other breast cancer treatment, such as radiation therapy or radiosurgery for certain types of metastases.
Making lifestyle changes may improve your quality of life. Exercise may also help lower the risk of TNBC recurrence. Your cancer care team can help create a plan to support your health and quality of life.
On MyBCTeam, people share their experiences with breast cancer, get advice, and find support from others who understand.
Do you have more questions about survival rates for people with triple-negative breast cancer? Let others know in the comments below.
Get updates directly to your inbox.
Continue with Facebook
Continue with Email
Continue with Facebook
Continue with Email
Become a member to get even more
Join
Your Privacy Choices
This is a member-feature!
Sign up for free to view article comments.
I have been stage 4 for 15 years. What's the stats for this?
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.